Medicare drug plans and retail pharmacy groups are working together to clean up the mess that plagued the launch of Part D. The manufacturers should pay attention: the result may be new force in drug selection and adherence.
By Cole Werble
The problems at the start of the Medicare outpatient drug benefit in January were painful for patients, pharmacists and prescription...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
CMS Administrator Mehmet Oz said PBMs may deserve "one last chance" to fix the rebate system before federal regulations and legislation are enacted.
Expanded confidential pricing for pharmaceuticals is intended to help manage medicines expenditure, according to Amgros, the procurement agency that will negotiate the prices.
The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.
Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.
Ongoing questions about user fees exerting too much influence over the FDA could spawn a shift in the PDUFA structure when talks begin later this year.
Vincenza Trivigno will take over as executive director from Raimund Bruhin, who is retiring after over seven years in the post.
Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.
